Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Looks To Recent Launches To Bolster Diovan Against Generic Onslaught

This article was originally published in The Pink Sheet Daily

Executive Summary

The Swiss pharma predicts hypertension blockbuster still will earn $2 billion annually outside the U.S. after patent expirations.
Advertisement

Related Content

Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
Bristol Myers-Squibb/AstraZeneca's Onglyza Officially Cleared For Europe
Bristol Myers-Squibb/AstraZeneca's Onglyza Officially Cleared For Europe
Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis
Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis
Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS069709

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel